Loading...
Loading...
The top 50 most commercially neglected diseases on earth, ranked by neglect score — the ratio of disease burden to research investment. These are the conditions that pharma ignores because there is no profit in curing them. MedicOath exists to change this.
Rapidly progressive gangrenous infection destroying facial tissue in malnourished children. 90% mortality without treatment. Survivors face severe disfigurement.
Why pharma ignores it: Affects only severely malnourished children in sub-Saharan Africa. Zero commercial interest. Only recently added to WHO NTD list.
Ultra-rare genetic disorder where muscles and connective tissue progressively turn to bone. No treatment or cure.
Why pharma ignores it: Fewer than 1,000 patients worldwide. Impossibly small market for any pharmaceutical company.
Extremely rare genetic condition causing rapid aging in children. Average lifespan is 14 years. Only ~400 cases known worldwide.
Why pharma ignores it: So rare that clinical trials are nearly impossible. No commercial pathway with ~400 patients globally.
Mycobacterial infection causing painless skin nodules that progress to large destructive ulcers. Third most common mycobacterial disease after TB and leprosy.
Why pharma ignores it: Rare, affects only tropical regions. Mechanism of pathogenesis still poorly understood.
Parasitic disease transmitted by sandflies causing fever, weight loss, spleen/liver enlargement. Fatal if untreated. Affects the poorest populations.
Why pharma ignores it: Patients too poor to pay. No market for treatments in sub-Saharan Africa and South Asia.
Parasitic disease transmitted by tsetse fly. Fatal without treatment. Causes sleep disturbance, confusion, and progressive neurological decline.
Why pharma ignores it: Exclusively affects rural sub-Saharan Africa. Treatment requires hospitalisation unavailable in endemic areas.
Parasitic infection causing heart failure and digestive complications. Endemic in Latin America. Existing treatments are toxic and poorly effective in chronic phase.
Why pharma ignores it: Endemic to impoverished rural regions. Existing drugs are 50+ years old with severe side effects.
Fatal genetic disorder causing progressive destruction of nerve cells in the brain and spinal cord. No treatment or cure.
Why pharma ignores it: Extremely rare. Gene therapy could theoretically treat it but no company will invest in a market of ~100 patients/year.
Chronic debilitating condition causing severe fatigue, post-exertional malaise, and cognitive dysfunction. No approved treatments.
Why pharma ignores it: Historically dismissed as psychosomatic. Receives less than $15 million/year in NIH funding despite affecting more people than MS.
Rare brain disorder causing problems with walking, balance, eye movements, and swallowing. Often misdiagnosed as Parkinson's.
Why pharma ignores it: Too rare for pharma ROI. Often misdiagnosed, so true prevalence is unknown.
Parasitic worm disease causing elephantiasis — extreme swelling of limbs and genitals. 120 million infected, 40 million disfigured.
Progressive neurodegenerative disorder affecting movement, blood pressure, and bladder function. No disease-modifying treatment exists.
Why pharma ignores it: Rare, rapidly fatal, difficult to diagnose. No commercial pathway.
Rapidly progressive and always fatal prion disease causing dementia, personality changes, and neurological decline.
Why pharma ignores it: Extremely rare prion disease — zero commercial incentive for drug development.
Parasitic worm infection affecting 240 million people. Causes chronic organ damage to liver, intestines, lungs, and bladder. Children are most affected.
Why pharma ignores it: Only drug (praziquantel) is 40 years old. No vaccine. R&D investment is a fraction of disease burden.
Heart failure occurring in the last month of pregnancy or within 5 months after delivery. Disproportionately affects women in sub-Saharan Africa.
Why pharma ignores it: Primarily affects women in low-income countries. Underfunded, underdiagnosed, poorly understood.
Group of rare genetic skin disorders causing extremely fragile skin that blisters with minor friction. Severe forms are debilitating and often fatal.
Why pharma ignores it: Rare, genetically heterogeneous. Gene therapy approaches exist but no commercial development pathway.
Parasitic worm infection causing severe itching, skin changes, and blindness. Second most common infectious cause of blindness.
100% fatal once symptomatic. Kills 59,000 people/year, mostly in Africa and Asia. Post-exposure prophylaxis exists but is inaccessible to many.
Why pharma ignores it: Vaccine exists but costs too much for endemic regions. 99% of deaths in countries that cannot afford post-exposure treatment.
Rare aggressive cancer of the bile ducts. Often diagnosed at advanced stage. Five-year survival under 10%.
Bacterial eye infection and leading infectious cause of blindness. Preventable but persists in the poorest communities.
Chronic bacterial infection causing skin lesions, nerve damage, and progressive disability. Curable with multi-drug therapy but stigma prevents treatment.
Age-related progressive loss of skeletal muscle mass and strength. Affects up to 30% of adults over 60 and 50% over 80.
Why pharma ignores it: Considered "normal aging" rather than a treatable disease. No FDA-approved treatments.
Aggressive cancer of the lining of lungs, caused by asbestos exposure. Median survival under 1 year. Very limited treatment options.
Inherited retinal dystrophy causing progressive vision loss and eventual blindness. No effective treatment for most genetic forms.
Genetic disorder causing brittle bones that fracture easily. Ranges from mild to lethal forms. No cure.
Fatal motor neuron disease causing progressive paralysis. No cure exists. Average survival is 2-5 years from diagnosis.
Why pharma ignores it: Small patient population makes drug development commercially unviable despite 100% fatality rate.
Chronic autoimmune disease causing hardening and tightening of skin and connective tissue. Can affect internal organs.
Inherited blood disorder causing misshapen red blood cells, pain crises, organ damage, and shortened lifespan. Disproportionately affects people of African descent.
Why pharma ignores it: Disproportionately affects Black populations in Africa and the diaspora. Historical funding disparities persist.
Bacterial infection killing 1.5 million people per year. Drug-resistant TB is a growing crisis. The BCG vaccine is over 100 years old.
Group of rare genetic disorders causing absent or dysfunctional T and B cells. Fatal without treatment. Known as "bubble boy disease".
Most aggressive brain cancer. Median survival 15 months. Standard of care has not changed significantly in 20 years.
Why pharma ignores it: Extremely difficult to treat due to blood-brain barrier. High failure rate makes pharma R&D investment risky.
Inherited neurodegenerative disorder causing uncontrolled movements, emotional problems, and loss of thinking ability.
Progressive scarring of lung tissue with no known cause. Median survival 3-5 years. Existing drugs slow but do not stop progression.
Rare genetic disorder causing progressive muscle weakness. Enzyme replacement is available but costs $300K+/year and has limited effectiveness.
Mosquito-borne parasitic disease killing 600,000+ people per year, mostly children under 5 in Africa.
Cancer developing from immature nerve cells, primarily in children under 5. High-risk forms have poor survival despite aggressive treatment.
Primary immunodeficiency causing low antibody levels and recurrent infections. Requires lifelong immunoglobulin replacement.
Mosquito-borne viral infection causing fever, severe joint pain, and potentially fatal hemorrhagic fever. 390 million infections per year.
Lifelong viral infection. HSV-1 affects 3.7 billion, HSV-2 affects 491 million. No cure, only suppressive therapy.
Why pharma ignores it: Pharma profits from lifelong suppressive therapy (acyclovir). A cure would eliminate a recurring revenue stream.
High blood pressure in pulmonary arteries causing right heart failure. Progressive and often fatal. Treatments exist but are expensive.
Rare adrenal insufficiency where adrenal glands produce insufficient hormones. Requires lifelong hormone replacement.
Genetic disorder causing fat buildup in organs. Enzyme replacement therapy exists but costs $200K-$400K per year.
Why pharma ignores it: Ultra-orphan drug market. Existing treatments are priced for maximum extraction from rare disease patients.
One of the deadliest cancers with only 12% five-year survival. Often diagnosed late. Limited treatment options beyond surgery.
Fatal genetic muscle disorder affecting boys. Progressive weakness leads to loss of walking, breathing, and death typically by age 30.
Inflammatory disease affecting blood vessels in children. Leading cause of acquired heart disease in children in developed countries.
Inherited metabolic disorder where the body cannot break down phenylalanine. Untreated, causes intellectual disability.
Chronic viral liver infection affecting 300 million people. Can cause liver cancer and cirrhosis. Functional cure remains elusive.
Chronic autoimmune disease where the immune system attacks multiple organs. Disproportionately affects women of colour.
Condition caused by prolonged exposure to high cortisol levels, causing weight gain, muscle weakness, and metabolic complications.
Neurological disorder causing recurrent seizures. 30% of patients do not respond to existing medications.